Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010

Infection Control and Hospital Epidemiology

Volumn 34, Issue 3, 2013, Pages 259-268

  Braykov, Nikolay P ^a   Eber, Michael R ^b   Klein, Eili Y ^a,c   Morgan, Daniel J ^d,e   Laxminarayan, Ramanan ^a,f,g  

^a Center for Disease Dynamics Economics and Policy   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^g PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREVALENCE; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AMBULATORY CARE FACILITIES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; CONFIDENCE INTERVALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NURSING HOMES; ODDS RATIO; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84873643362     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/669523     Document Type: Article

References (40)

1. de Kraker M, Wolkewitz M, Davey P, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66(2):398-407.
2. Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care 2011;17(5):472-479.
3. Paterson D. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4):657-686.
4. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56(1):52-59.
5. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42(suppl 4):S164-S172.
6. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52(3):813-21.
7. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011;17(10): 1791-1798.
8. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-pro-ducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8(3):159-166.
9. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53(1):60-67.
10. Lledo W, Hernandez M, Lopez E. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWRMorb Mortal Wkly Rep 2009;58(10):256-260.
11. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 2009;180(4):408-415.
12. Nadkarni AS, Schliep T, Khan L, Zeana CB. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am J Infect Control 2009; 37(2):121-126.
13. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165: 1430-1435.
14. Centers for Disease Control and Prevention. Carbapenemresistant Klebsiella pneumoniae associated with a long-term-care facility: West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep 2011;306(23):2558-2560.
15. Chitnis AS, Caruthers PS, Rao AK, et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33(10):984-992.
16. Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis 2008;47(suppl 1):S21-S31.
17. Arnold R, Thom K, Sharma S, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. Southern Med 2011;104(1):40-45.
18. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):996-1011.
19. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999; 29(2):259-263.
20. Klein E, Smith DL, Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis 2009;15(12):1925-1930.
21. Hoffmann MS, Eber MR, Laxminarayan R. Increasing resistance of Acinetobacter species to imipenem in United States hospitals, 1999-2006. Infect Control Hosp Epidemiol 2010;31(2):196-197.
22. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004;3:3.
23. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. Wayne, PA: CLSI, 2010.
24. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:5512-5528.
25. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012;4(148):148-116.
26. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum betalactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32(suppl 2):S94-S103.
27. Marquez P, Terashita D, Dassey D, Mascola L. Community-wide Laboratory Surveillance of Carbapenem-Resistant Klebsiella pneumoniae (CRKP): Los Angeles County 2010. In: Program and abstracts of the 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA); April 1-4, 2011; Dallas, TX; Abstract 359.
28. Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 2012;55(3):1-8.
29. Boyd LB, Atmar RL, Randall GL, et al. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 2008;8:4.
30. Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011;66(6):1409-1411.
31. Jones RN, Sader HS, Fritsche TR. Occurrences of Extended Spectrum and Other Beta-Lactamases among Enterobacteriaceae Isolated in USA Medical Centers: 10-Year Report from the SENTRY Antimicrobial Surveillance Program. In: Program and abstracts of the 45th Annual Meeting of the Infectious Disease Society of America; 2007; San Diego, CA; Abstract 473.
32. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65(4):414-26.
33. Bulik CC, Fauntleroy KA, Jenkins SG, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010;48(7):2402-2406.
34. Rhomberg PR, Moet GJ, Sader HS, Farrelll DJ, Jones RN. Impact Assessment of Revised CLSI Cephalosporin Breakpoints (M100-S20, 2010) Using 27,415 Enterobacteriaceae Isolates Tested in the SENTRY Antimicrobial Surveillance Program. In: Program and Abstracts of the 48th Annual Meeting of the Infectious Disease Society of America; October 20-24, 2010; Vancouver, BC, Canada; Abstract 1016.
35. Kallen AJ, Beekmann SE, Limbago B, et al. Prevalence of betalactam nonsusceptible gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians. Diagn Microbiol Infect Dis 2011; 71(3):316-319.
36. Master RN, Draghi DC, Jones ME, et al. Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003. Ann Clin Microbiol Antimicrobial 2004;3:1.
37. Bell JM, Chitsaz M, Turnidge JD, et al. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveil. J Clin Microbiol 2007; 45(5):1478-1482.
38. Munier GK, Johnson CL, Snyder JW, et al. Positive extendedspectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs. J Clin Microbiol 2010;48(2):673-674.
39. Centers for Disease Control and Prevention. Carbapenemresistant enterobacteriaceae containing New Delhi metallo-betalactamase in two patients-Rhode Island, March 2012. MMWR Morb Moral Wkly Rep 2012;61(24):446-448.
40. Schwaber MJ, Lev B, Israeli A, et al. Containment of a countrywide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52(7):848-855.